Scholarlink

<p>The lack of tumor targeting ability and the failure of single therapeutic approaches are two challenges in the treatment of pancreatic cancer. Mesoporous silica (MS) nanoparticles of two sizes (MS50 and MS100) were fabricated and functionalized with polydopamine (PD), cercosporin (CE), and arginine-glycine-aspartic acid peptide (RP) for the dual purposes of photodynamic therapy (PDT) and photothermal therapy (PTT) aimed at integrin αvβ3 in pancreatic cancer. MS@PD-RP-CE were examined using several approaches, exhibiting selective drug release, enhanced photothermal conversion efficiency, and reactive oxygen species (ROS) generation under laser irradiation. MS100@PD-RP-CE exhibited enhanced cellular uptake and cytotoxicity against pancreatic cancer (PANC-1) in vitro, while selectively targeting pancreatic cancer cells over normal cells, in comparison to MS50@PD-RP-CE. The mechanism of cell death was analyzed utilizing Calcein-AM/PI, and nuclear staining techniques. MS100@PD-RP-CE demonstrated considerable biocompatibility, as shown by the hemolytic assay. Thus, MS100@PD-RP-CE demonstrates significant promise for the prospective treatment of pancreatic cancer.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fabrication of cercosporin-loaded polydopamine- cloaked mesoporous silica nanoparticles enhanced photothermal-photodynamic and anticancer activity in pancreatic cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月27日

查看全文
  • Jingsheng Hua,
  • Bo Ning,
  • Hongxin Zhang

摘要

The lack of tumor targeting ability and the failure of single therapeutic approaches are two challenges in the treatment of pancreatic cancer. Mesoporous silica (MS) nanoparticles of two sizes (MS50 and MS100) were fabricated and functionalized with polydopamine (PD), cercosporin (CE), and arginine-glycine-aspartic acid peptide (RP) for the dual purposes of photodynamic therapy (PDT) and photothermal therapy (PTT) aimed at integrin αvβ3 in pancreatic cancer. MS@PD-RP-CE were examined using several approaches, exhibiting selective drug release, enhanced photothermal conversion efficiency, and reactive oxygen species (ROS) generation under laser irradiation. MS100@PD-RP-CE exhibited enhanced cellular uptake and cytotoxicity against pancreatic cancer (PANC-1) in vitro, while selectively targeting pancreatic cancer cells over normal cells, in comparison to MS50@PD-RP-CE. The mechanism of cell death was analyzed utilizing Calcein-AM/PI, and nuclear staining techniques. MS100@PD-RP-CE demonstrated considerable biocompatibility, as shown by the hemolytic assay. Thus, MS100@PD-RP-CE demonstrates significant promise for the prospective treatment of pancreatic cancer.